
Pearson Lab
@lab_pearson
Followers
853
Following
409
Media
88
Statuses
491
University of Chicago head and neck cancer lab doing research at the interface of computational methods, tumor biology, and clinical relevance. PI: Alex Pearson
Hyde Park, Chicago
Joined May 2018
RT @CancerCoreEU: 🤖 Join the Artificial Intelligence in Cancer Research Summer School 2025 hosted by @IstTumori- A pioneering event where c….
0
2
0
RT @UCCancerCenter: At #ASCO25, Frederick Howard, MD, presents a poster showing high efficiency of AI models that accurately predicts treat….
0
3
0
RT @UCCancerCenter: From ambient dictation tools to FDA-approved diagnostics, #AI is transforming oncology!.At #ASCO25, Alexander Pearson,….
0
4
0
RT @AriRosenbergMD: 🧐Our DEPEND trial is out! Neoadjuvant nivo/chemo followed by response-stratified CRT in HPV-negative stage IVa/b HNSCC.….
jamanetwork.com
This phase 2 nonrandomized clinical trial evaluates the deep response rate and tolerability of neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in...
0
22
0
Jazzed to see our work describing *potential LLM use trends in @ASCO abstracts* as one of the @JCO_ASCO family top articles of 2024. Check out all the top articles here: @fredhow @LGM_Biostats @JCOCCI_ASCO @UCCancerCenter @UChicagoBSD.
ascopubs.org
0
4
13
RT @PrelajArsela: The #callforabstracts for our annual AI for Oncology conference in @IstTumori (May 8-9, 2025) is open until Feb 3rd - htt….
0
9
0
Thanks so much @BasuLab1 @LovaSunMD @PennHeadandNeck! What a great opportunity to brainstorm science together.
It was a privilege to host @lab_pearson together with @LovaSunMD as part of our Head and Neck Cancer Center of Excellence lecture series and learn about progress toward AI-based discrimination of actionable states for cancer therapy.
0
1
16
RT @NatureBiotech: Generative artificial intelligence for drug discovery: how the first AI-discovered and AI-designed drug progressed to….
communities.springernature.com
Here, we summarize and contextualize the findings of a recent Nature Biotechnology publication by Insilico Medicine. We discuss the multimodule generative AI pipeline and robotics underlying the...
0
12
0
RT @AkashPatnaik7: Honored to present our translational research at @TheVFoundation symposium. Thank you for the invtation and your support….
0
3
0
RT @WF_Parker: Incredibly excited to share our open-source Common Longitudinal ICU data Format (CLIF)! We hope CLIF will substantially impr….
0
7
0
RT @JamesDolezal: 🚀 Big news! Slideflow 3.0 is here! 🎉 We've revamped our licensing (now Apache-2.0) to make Slideflow more open & accessib….
github.com
Powerful, open-source AI tools for digital pathology. - slideflow/slideflow
0
4
0
Fantastic news!.
Thank you @woldloren! I am honored to receive this award from @ConquerCancerFd. I have been blessed with incredible mentorship on this project from the Applebaum lab @UChiPritzker @d_golden @lab_pearson & @spshubeck. Excited to present @ASCO!. @FutureDocs.
0
0
4
RT @ajuloorimd: Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for….
0
11
0
Looking forward to this terrific session!.
🔜#ASCOBT24 Day1⃣.🔥Artificial Intelligence in the Cancer Clinic.✅Overview: Chair &🎙️@lab_pearson.✅Pathology: 🎙️Joe Poh Sheng Yeong.✅Large Language Models:🎙️Danielle Sara Bitterman.✅Precision oncology: 🎙️Caroline Chung.@OncoAlert @ASCO @JSMO_official.
0
1
8
RT @UChicagoMed: U.S. News & World Report's Best Hospitals list ranked University of Chicago Medical Center's Cancer and ENT programs highe….
0
11
0
Ecstatic to join 1st cohort of #CZBiohubCHI Investigators, with @EsserKahnLab + Peter Maurer. Our squad will use quantum-enabled IDs⚛️to eval individual immune cells in real-time to describe disease like malignant transformation🦀. @czbiohub @UChicagoMed @UChicago @UCCancerCenter.
🎉Congratulations to the 2024 #CZBiohubCHI Investigators! The cohort of 48 of Chicago’s most creative and accomplished scientists and engineers will use multidisciplinary approaches to understand inflammation and the dysregulation of immune cells.
1
0
10
RT @ElinardouHelena: Priviliged to have spent 4 days with friends and colleagues from all over the 🌎in the beautiful historic setting of AK….
0
4
0
Ugh. Program termination applies to: .TrilynX (NCT04459715).XRAY VISION (NCT05386550).
BAD NEWS! -- Xevinapant +cis in HN Phase 3 negative at interim -- cis ineligible study closing down -- not great news for #hncsm #radonc @NRGonc .(h/t @yaoyu_md) @CJTsaiMDPhD @KaramLab @imrtlee @HenningWillers .
0
0
6
RT @UCCancerCenter: @fredhow and colleagues published a great study in @JCOCCI_ASCO during #ASCO24 reporting increased use of AI tools in s….
0
1
0